Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I clinical trial of HRS-9057 for injection - Safety, tolerability, pharmacokinetics and pharmacodynamics of a single dose of HRS-9057 for injection

Next Previous
Trial Profile

Phase I clinical trial of HRS-9057 for injection - Safety, tolerability, pharmacokinetics and pharmacodynamics of a single dose of HRS-9057 for injection

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 24 Oct 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs HRS 9057 (Primary)
  • Indications Heart failure
  • Focus Adverse reactions

Most Recent Events

  • 12 Jul 2024 New trial record
  • 09 Jul 2024 According to Fujian Shengdi Pharmaceutical media release, the Company received the "Notice of Approval for Drug Clinical Trial" approved and issued by the National Medical Products Administration, approving the clinical trial of HRS-9057,drug for injection, for the treatment of fluid retention caused by heart failure.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top